Condiciones de salud que equinácea purpúrea puede ayudar a apoyar.
In vitro research demonstrates that standardized E. purpurea extract (Echinaforce®) kills Propionibacterium acnes and suppresses the pro-inflammatory cytokine cascade the bacterium induces. The EMA HMPC monograph and official herbal monographs list mild acne among recognized indications. Evidence is currently preclinical and in vitro, not yet confirmed by clinical RCTs.
E. purpurea extracts are well-characterized antioxidants, with in vitro and ex vivo studies demonstrating suppression of intracellular reactive oxygen species (ROS) and nitrogen species (RNS). The antioxidant capacity has been quantified by DPPH, ABTS, ORAC, and HORAC assays. Caffeic acid derivatives are the principal antioxidant contributors.
Echinacea purpurea is the most clinically studied of the Echinacea species for acute respiratory infections including bronchitis. A 2023 mechanistic systematic review in Pharmaceuticals confirmed its immunomodulatory mechanism in acute respiratory infections. Multiple RCTs and meta-analyses show reductions in respiratory illness incidence and duration when taken preventively or at illness onset.
Echinacea purpurea is the most studied Echinacea species for respiratory tract infections including bronchitis. Multiple RCTs and systematic reviews, including Cochrane assessments, found statistically significant reductions in respiratory infection symptom duration and severity. Its polysaccharides and alkylamides drive immunostimulation and anti-inflammatory effects in bronchial tissue.
Echinacea purpurea specifically has been studied in the context of oral aphthous ulcers for its immunomodulatory and anti-inflammatory properties. A clinical trial (PMC6131317) using echinacea tablets in 50 patients with recurrent minor oral aphthous ulcers found positive effects on healing and reduction in recurrence. Its polysaccharides and caffeic acid derivatives are proposed as the primary active agents reinforcing immune function in RAS.
Echinacea purpurea is the most studied Echinacea species for children's immune and respiratory health. Clinical trials specifically using E. purpurea demonstrated reduced respiratory tract infection rates and reduced antibiotic use in children. A 2025 systematic review and meta-analysis confirmed efficacy for treating URTI and otitis media complications in children.
Multiple in vitro studies using human primary macrophages confirm that E. purpurea extracts—particularly alkylamide-enriched fractions—significantly reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and reactive oxygen/nitrogen species. In vivo, the extract modulates the TNF-α/IL-10 axis. Clinical application to chronic inflammatory disease remains under investigation.
Echinacea purpurea is the most clinically studied Echinacea species for cold and flu. Multiple RCTs and systematic reviews indicate it reduces duration and severity of upper respiratory tract infections. A 2015 noninferiority trial comparing it to oseltamivir for influenza showed comparable efficacy. Cochrane reviewers concluded it was effective in 5 of 6 treatment trials reviewed.
E. purpurea specifically has been tested against acyclovir-susceptible and acyclovir-resistant HSV strains in vitro, showing significant antiviral activity at non-cytotoxic concentrations. A polysaccharide fraction reduced HSV-1 latency in mice. Cichoric acid and alkylamides are the primary active anti-HSV constituents.
Echinacea purpurea is the most studied Echinacea species for respiratory infections, with clinical trials showing reductions in cold and upper respiratory infection duration and severity. It is recognized by the German Commission E and NCCIH for supportive treatment of upper respiratory tract infections relevant to lung defense.
Echinacea purpurea has the strongest clinical evidence among Echinacea species for acute respiratory infections, with a systematic meta-analysis of nine studies confirming reduced URTI incidence, duration, and antibiotic usage in children. German Commission E and WHO positively evaluated it. A randomized trial demonstrated an E. purpurea, propolis, and vitamin C preparation significantly prevented respiratory infections in children aged 1–5.
The most extensively studied Echinacea species, E. purpurea extracts have been shown in controlled clinical trials to stimulate innate immunity (macrophages, NK cells) and reduce duration and severity of upper respiratory illness. A systematic review confirmed immunomodulatory efficacy, supporting its use during and after illness for recovery.
Echinacea purpurea is the most clinically studied echinacea species, with multiple RCTs supporting its immunomodulatory and antiviral actions relevant to recovery from viral respiratory infections. It contains alkylamides and polysaccharides that modulate innate immune activation and suppress excessive cytokine release. Commission E and ESCOP recognize its use for supporting immune function in upper respiratory illness.
E. purpurea has the most extensive clinical evidence base of all its applications in the prevention and treatment of seasonal upper respiratory tract infections. Multiple RCTs, a 2014 Cochrane review of 24 trials, and NCCIH/EMA recognition support this use, though results are heterogeneous across formulations.
Echinacea purpurea is the most studied echinacea species for upper respiratory tract infections with nasal congestion. Multiple RCTs, a 2019 meta-analysis, and NCCIH acknowledge that some E. purpurea preparations may be more effective than placebo for reducing cold symptoms including nasal congestion, though overall evidence is weak. Native American traditional use for respiratory infections and nasal symptoms is well-documented.
Echinacea purpurea is the most studied species in RTI and sinusitis research. A pediatric RCT demonstrated it reduced viral RTIs leading to bacterial sinusitis complications compared to vitamin C control. The meta-analysis ERA-PRIMA (2024) specifically included E. purpurea preparations in trials documenting reduced sinusitis complications.
Echinacea purpurea is the species most studied for upper respiratory infections and sore throat. The 2009 randomized double-blind trial (Schapowal et al.) used a purpurea-based spray and showed equivalence to chlorhexidine/lidocaine spray for acute sore throat over 5 days. Cochrane data support E. purpurea specifically for cold prevention and duration reduction.
Echinacea purpurea specifically has been investigated for immune modulation and upper respiratory tract infection management including tonsillopharyngitis. A cell-model study using human tonsil epithelial cells (HTonEpiC) showed E. purpurea extracts suppress inflammatory biomarkers relevant to streptococcal tonsillitis. It is commonly recommended in traditional European and North American herbalism for tonsillitis.
Echinacea purpurea is the most clinically studied Echinacea species for URTI. Randomized controlled trials demonstrate it reduces severity and duration of cold symptoms. A 2025 meta-analysis of 9 RCTs in children confirmed its efficacy for URTI treatment and prevention of otitis media complications.
Echinacea purpurea is the most studied species for antiviral immune support, with RCT evidence showing reduced coronavirus and influenza viral loads, shortened illness duration, and immune modulation via macrophage activation and cytokine regulation. Clinical studies confirm virucidal activity against enveloped respiratory pathogens.
The EMA HMPC officially recognizes E. purpurea aerial part preparations for alleviation of skin disorders and minor wounds. In vitro studies show E. purpurea extracts accelerate wound closure by increasing cell migration and promoting TGF-β1 expression. This is supported by antioxidant and anti-inflammatory mechanisms.
Echinacea purpurea has a well-documented history of traditional use for skin infections including abscesses, boils, and carbuncles. It was regarded historically as an 'anti-infective' agent for furunculosis and similar skin conditions. No robust clinical trials specifically addressing abscess treatment with E. purpurea have been conducted.
Traditional contraindication listings from the German Commission E, WHO, and ESCOP caution against E. purpurea use in autoimmune diseases such as multiple sclerosis, lupus, and collagen disorders, based on theoretical immune stimulation concerns. More recent pharmacological evidence suggests lipophilic alkamide-containing preparations may instead suppress cellular immunity, complicating the picture.
Native American peoples used E. purpurea topically for insect stings and snake bites for centuries, representing one of the herb's most historically consistent traditional applications. This use is well-documented in ethnobotanical literature but lacks controlled clinical trial evidence.
Echinacea purpurea is used in European and North American traditional medicine for fever associated with colds, flu, and upper respiratory tract infections. Native Americans used related Echinacea species as antipyretics. The German Commission E approves E. purpurea for febrile infections and upper respiratory conditions.
E. purpurea has traditional use for fungal skin and urogenital infections, supported by early clinical reports and in vitro evidence of antifungal activity against clinically isolated fungi. Controlled clinical trial evidence is limited and of questionable validity by modern standards.
Echinacea purpurea has a documented traditional use in Western herbalism and Native American medicine for supporting lymphatic and immune function, used to treat swollen lymph nodes and cleanse the lymphatic system. Modern pharmacological research supports stimulation of phagocytosis and lymphocyte proliferation. Direct clinical evidence for lymphatic drainage specifically is limited, but indirect immunological evidence supports its traditional application.
Echinacea purpurea specifically has documented use in North American and European herbal traditions for supporting the lymphatic and immune systems. Modern research shows E. purpurea extract modulates dendritic cell trafficking and mobility, relevant to lymphatic antigen transport. Direct human evidence for lymphatic drainage endpoints is lacking; this is primarily a traditional use supported by immunological mechanistic studies.
E. purpurea has traditional use for nasopharyngeal catarrh and conditions involving excess mucus as part of upper respiratory tract infections. The German Commission E, WHO, and ESCOP monographs list respiratory catarrh among the traditional indications. Clinical trials have not isolated mucus reduction as a specific outcome measure.
Echinacea purpurea is one of the two Echinacea species most commonly cited in Eclectic and modern herbal pertussis protocols as an immune stimulant and lymphatic agent. It appears in the ADAM Complementary and Alternative Medicine pertussis resource and its species-specific immunological properties are documented in a 2005 evidence-based systematic review.
Echinacea purpurea is the most commercially prominent and clinically studied Echinacea species, used in traditional North American herbal medicine for immune support during infections. Some herbal authorities list it for UTI support via immune modulation. Direct clinical evidence for UTI is lacking; the mechanism would be immunological support rather than direct urinary antisepsis.
Echinacea purpurea is the primary Echinacea species used commercially and proposed in integrative medicine as an immune adjunct for HPV wart management. The only direct RCT (Zedan et al., 2009; 135 patients) found oral echinacea did not significantly outperform placebo for wart clearance. Its immunostimulatory mechanisms are established for other indications but have not been demonstrated to translate to wart clearance.
Volver